Everything below concerns peptide agonist. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-10-30. Numbers and descriptions here follow the published literature rather than marketing material.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Not a small molecule |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist activity |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Soluble in water | Also in aqueous buffers |
| Storage | −20 °C or below | Protect from light and moisture |
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
瑞他鲁肽是一种在研合成肽，同时作用于胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽和胰高血糖素受体。该分子属于多受体激动剂类别，尚未获得任何监管机构的上市批准。当前临床开发主要针对肥胖和2型糖尿病，研究代号为LY3437943。已确立的信息包括受体靶点和部分中期试验结果；最终疗效、长期安全性和适用人群仍属开放问题。
开发进程从早期单次和多次给药研究推进至大规模后期试验。公开报告显示，参与者在体重和相关代谢指标上出现变化，但完整数据需经同行评审并接受独立复核。试验设计通常包括随机、双盲和对照设置，以区分药物效应与行为干预。监管提交和标签范围尚未确定；长期维持效果与心血管结局仍是开放问题。
与仅靶向单一受体的同类药物相比，瑞他鲁肽增加胰高血糖素受体成分，理论上可提高能量消耗并改变脂肪分布。临床中观察到的体重变化是否主要来自该额外机制，目前尚无定论。胃肠道反应是该类药物常见不良事件，试验中通过剂量递增和监测进行管理。停药后体重反弹、个体差异和长期耐受性仍需更多数据。
== Application == One of the primary applications of hybrid containers is in pharmaceutical cold-chain logistics to keep pharmaceutical products, such as vaccines or active ingredients, within strict temperature ranges. Currently, this technology is only being used in a limited number of shipping containers. Examples of hybrid shipping container systems include SkyCell 1500X, SkyCell 6500X, va-Q-tec va-Q-one, and Tower Cold Chain KTEvolution. Other temperature-controlled container providers, including Peli BioThermal and World Courier, offer solutions incorporating thermal energy storage and advanced insulation technologies.
Based on coalescence of Mitochondrial DNA and Y Chromosome data, the earliest extant lineages of modern humans on the Indian subcontinent had reached there from Africa between 80,000 and 50,000 years ago, and with high likelihood by 55,000 years ago. Neolithic and chalcolithic cultures arose in the western margins of the Indus river basin around Mehrgarh in Balochistan, Pakistan after 7000 BCE. These gradually evolved into the Indus Valley Civilisation, which flourished during 2500–1900 BCE in Pakistan and western India. Centred around cities such as Mohenjo-daro, Harappa and Dholavira, its characteristic features included steatite seals, a written script, urban planning, terracotta human figures and animal statuettes. Between 1500 BCE and 1200 BCE, an archaic form of Sanskrit, an Indo-European language, diffused into India from the northwest. Its evidence today is found in the Rig Veda—the scripture associated with the historical Vedic religion, one of the progenitors of what later became Hinduism. The settling of the Ganges river plain took place during the next millennium, when swathes of the river system's adjoining regions were deforested and prepared for agriculture. The Dravidian and other languages of India were supplanted in the north, creating a broad language family-divide, with the Indo-Aryan languages being spoken mainly in the north and west, and the Dravidian in some parts of east India and most of the south. A second urbanisation took place in India by the middle-first-millennium BCE.
Three years later, the 2013 revision of the "phenotypes for the disease course" were forced to consider CIS as one of the phenotypes of MS, making obsolete some expressions like "conversion from CIS to MS". Other organizations have proposed later new clinical phenotypes, like HAMS (Highly Active MS).
Sources: en.wikipedia.org
Long after the Cisplatine War that resulted in the independence of Uruguay, Brazil won three international wars during the 58-year reign of Pedro II: the Platine War, the Uruguayan War and the devastating Paraguayan War, the largest war effort in Brazilian history. Although there was no desire among the majority of Brazilians to change the country's form of government, on 15 November 1889, in disagreement with the majority of the Imperial Army officers, as well as with rural and financial elites, the monarchy was overthrown by a military coup. A few days later, the national flag was replaced with a new design that included the national motto "Ordem e Progresso", influenced by positivism. 15 November is now Republic Day, a national holiday.
In addition, the Kanji of the Year (kotoshi no kanji) has been selected since 1995, and both the kanji and the word/phrase of the year often reflect current Japanese events and attitudes. For example, in 2011, following the Fukushima nuclear disaster, the frustratingly enigmatic phrase used by Japanese officials before the explosion regarding the possibility of a meltdown - "the possibility of recriticality is not zero" (Sairinkai no kanōsei zero de wa nai) - became the top phrase of the year. In the same year, the kanji for "bond" (i.e., family ties or friendship) became the kanji of the year, expressing the importance of collectiveness in the face of disaster. Liechtenstein: Word of the year (Liechtenstein) since 2002. In Norway, the Word of the year poll has been carried out since 2012. In Portugal, the Word of the year poll has been carried out since 2009. In Russia, the Word of the year poll has been carried out since 2007. In Slovenia, the word of the year poll has been carried out since 2016. Each year, it is announced in January together with the SSL (Slovenian Sign Language) gesture of the year. In Spain, a Word of the year has been selected by Fundéu since 2013. Switzerland: Word of the year (Switzerland), since 2003. In Ukraine, the Word of the year poll has been carried out since 2013. In The Netherlands, a word of the year poll is carried out by dictionary publisher Van Dale since 2007.
Many carboxylases, including acetyl-CoA carboxylase, methylcrotonyl-CoA carboxylase, propionyl-CoA carboxylase, and pyruvate carboxylase require biotin as a cofactor. These enzymes are involved in various anabolic pathways. In the EC scheme, such carboxylases are mostly classed under EC 6.4.1, ligases “forming carbon-carbon bonds,” or sometimes EC 6.3.4, "Other Carbon—Nitrogen Ligases". Another example is the posttranslational modification of glutamate residues, to γ-carboxyglutamate, in proteins. It occurs primarily in proteins involved in the blood clotting cascade, specifically factors II, VII, IX, and X, protein C, and protein S, and also in some bone proteins. This modification is required for these proteins to function. Carboxylation occurs in the liver and is performed by γ-glutamyl carboxylase (GGCX). GGCX requires vitamin K as a cofactor and performs the reaction in a processive manner. γ-carboxyglutamate binds calcium, which is essential for its activity. For example, in prothrombin, calcium binding allows the protein to associate with the plasma membrane in platelets, bringing it into close proximity with the proteins that cleave prothrombin to active thrombin after injury.
Sources: en.wikipedia.org
The investigators found that SAGE systems were nontoxic in vivo, and were capable of eliciting CD4 T cell and B cell responses in the case of the tetanus toxoid and ovalbumin systems while eliciting a CD8 T cell response with the hemagglutinin system. Some advantages to using SAGE systems for antigen presentation include the ability to remain stable and functional after functionalization with cargo, the ability to modify and tune cellular uptake properties, and the modularity of the platform which could potentially be used to present multiple antigens at the same time, resulting in increased antigen immunogenicity. Another type of coiled-coil nanoparticle system is the self-assembling protein nanoparticles (SAPN). SAPN differs from SAGE in that SAPN utilizes trimeric and pentameric coiled-coil motifs. This change results in the self-assembly of a symmetrical polyhedral 16 nm nanoparticle composed of 60 monomer building blocks. The small size of SAPN allows the nanoparticle system to resemble viruses in shape and size, which is beneficial to antigen presentation. Specifically, SAPN has been utilized by Dr. David Lanar and colleagues to develop a P. falciparum malaria vaccine whereby B and CD8-T cell epitopes of the disease were modified into the SAPN coiled-coil motifs. In vivo results showed that a long-lasting immune response was generated in the mice for up to 13 months, capable of preventing malaria infection in vaccine-treated mice.
Opioid peptides or opiate peptides are peptides that bind to opioid receptors in the brain; opiates and opioids mimic the effect of these peptides. Such peptides may be produced by the body itself, for example endorphins. The effects of these peptides vary, but they all resemble those of opiates. Brain opioid peptide systems are known to play an important role in motivation, emotion, attachment behaviour, the response to stress and pain, control of food intake, and the rewarding effects of alcohol and nicotine. Opioid-like peptides may also be absorbed from partially digested food (casomorphins, exorphins, and rubiscolins). Opioid peptides from food typically have lengths between 4–8 amino acids. Endogenous opioids are generally much longer. Opioid peptides are released by post-translational proteolytic cleavage of precursor proteins. The precursors consist of the following components: a signal sequence that precedes a conserved region of about 50 residues; a variable-length region; and the sequence of the neuropeptides themselves. Sequence analysis reveals that the conserved N-terminal region of the precursors contains 6 cysteines, which are probably involved in disulfide bond formation. It is speculated that this region might be important for neuropeptide processing.
== Interactions == Buprenorphine's sedating/narcotic effect is increased by other sedating substances, such as other opioids, benzodiazepines, first-generation antihistamines, alcohol, and antipsychotics. Opioids and especially benzodiazepines also increase the risk of potentially lethal respiratory depression. Strong inhibitors of the liver enzyme CYP3A4, such as ketoconazole, moderately increase buprenorphine concentrations; CYP3A4 inducers can theoretically decrease concentrations of buprenorphine.
== Research == In 2015, Merck reported results in thirteen cancer types; much attention was given to early results in head and neck cancer. As of May 2016, pembrolizumab was in phase IB clinical trials for triple-negative breast cancer (TNBC), gastric cancer, urothelial cancer, and head and neck cancer (all under the "Keynote-012" trial) and in phase II trial for TNBC (the "Keynote-086" trial). At ASCO, in June 2016, Merck reported that the clinical development program was directed to around 30 cancers and that it was running over 270 clinical trials (around 100 in combination with other treatments) and had four registration-enabling studies in process. Results of a phase III clinical trial in triple-negative breast cancer were reported in October 2019. Results of a phase II clinical trial in Merkel-cell carcinoma were reported in June 2016. Results of a clinical trial in people with untreatable metastases arising from various solid tumors were reported in 2017. A clinical phase III trial in combination with epacadostat, an Indoleamine 2,3-dioxygenase (IDO1) inhibitor to treat melanoma was completed in 2019. In 2021, researchers reported the results of a five-year follow-up study. In January 2022, a combination clinical trial of pembrolizumab and NL-201, a de novo protein undergoing a phase I clinical trial in people with advanced, relapsed or refractory solid tumors. In March 2023, Merck reported the results of NRG-GY018, a phase III clinical trial in people with stage three to four or recurrent endometrial carcinoma.
Sources: en.wikipedia.org
Retatrutide is an investigational synthetic peptide that activates three metabolic receptors: GLP-1, GIP, and glucagon. It is being studied for obesity and type 2 diabetes. It has not been approved for clinical use.
Earlier incretin therapies engage one or two receptors. Retatrutide adds glucagon receptor activity, which may raise energy expenditure. Whether this produces larger clinical benefits is still being tested.
It has completed phase 2 trials and moved into later-stage evaluation. No regulator has granted approval. Access outside research settings is not authorized.
As of the mid-2020s retatrutide remains investigational and is not an approved medicine in the United States or the European Union. It has been supplied mainly to participants in clinical trials. Labels and availability can change, so regulatory listings should be checked directly.